You have read all your free articles, to continue reading subscribe to read the rest of this content.
Calliditas Therapeutics has announced positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, which investigated the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The trial met its primary objective of demonstrating a statistically sAlready a subscriber Login You have read…
Affibody has announced that its partner Daewoong, a South Korea-based pharmaceutical company, has exercised an option under the companies’ ongoing collaboration. “We are pleased to announce that our longtime partner Daewoong has decided to exercise their option to develop and commercialize anAlready a subscriber Login You have read all your…
Cobra Biologics and Alligator Bioscience extend their drug development partnership. The project will deliver second cell line for manufacture of immuno-oncology antibody ADC-1015 following ADC-1013 success. Cobra Biologics (Cobra), an international CDMO of biologics and pharmaceuticals, has been Already a subscriber Login You have read all your free articles, to…
AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for an additional dosing option, a 1,500mg fixed dose every four weeks, in the approved indications of unresectable Stage III non-small cell lung cancer (NSCLC) after chemoradiation therapy (CRT) and previously treated advanced bladdAlready a subscriber Login You have read all your free…
